Evidence map›Paper›PMID 41111282›Full record

ArticleBritish journal of haematology2026

Impact of methotrexate-dosing regimens for GVHD prophylaxis on clinical outcomes of HLA-matched allogeneic HSCT.

Tomotaka Suzuki, Tomoyasu Jo, Kota Yoshifuji, Tadakazu Kondo, Noriko Doki, Yoshinobu Kanda, Tetsuya Nishida, Yasushi Onishi, Noboru Asada, Takahiro Fukuda and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Tomotaka SuzukiDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.ORCID https://orcid.org/0000-0001-5694-8501
Tomoyasu JoDepartment of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0001-9381-0421
Kota YoshifujiDepartment of Hematology, Institute of Science Tokyo, Tokyo, Japan.ORCID https://orcid.org/0009-0000-9206-3137
Tadakazu KondoDepartment of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0002-8959-6271
Noriko DokiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital, Tokyo, Japan.
Yoshinobu KandaDivision of Hematology, Jichi Medical University Saitama Medical Centre, Saitama, Japan.ORCID https://orcid.org/0000-0002-4866-9307
Tetsuya NishidaDepartment of Hematology, Japanese Red Cross Aichi Medical Centre Nagoya Daiichi Hospital, Nagoya, Japan.
Yasushi OnishiDepartment of Hematology, Tohoku University Hospital, Sendai, Japan.
Noboru AsadaDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.ORCID https://orcid.org/0000-0001-7322-5460
Takahiro FukudaDepartment of Haematopoietic Stem Cell Transplantation, National Cancer Centre Hospital, Tokyo, Japan.
Masashi SawaDepartment of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
Yuta HasegawaDepartment of Hematology, Hokkaido University Hospital, Sapporo, Japan.
Kentaro SerizawaDepartment of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osakasayama, Japan.
Shuichi OtaDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.ORCID https://orcid.org/0000-0002-3631-244X
Masatsugu TanakaDepartment of Hematology, Kanagawa Cancer Centre, Yokohama, Japan.
Makoto YoshimitsuDepartment of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.ORCID https://orcid.org/0000-0002-5935-0385
Yoshiko AtsutaJapanese Data Centre for Haematopoietic Cell Transplantation, Nagoya, Japan.ORCID https://orcid.org/0000-0003-4404-2870
Junya KandaDepartment of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0002-6704-3633

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe graft-versus-host disease (GVHD) remains a major complication of allogeneic haematopoietic stem cell transplantation (allo-HSCT), necessitating optimal immunosuppressive strategies. This retrospective study used data from the Japanese Transplant Registry Unified Management Program to compare three methotrexate (MTX)-dosing regimens for GVHD prophylaxis in patients undergoing human leucocyte antigen (HLA)-matched allo-HSCT: a low-dose 3-day regimen (Ld3:10 mg/m

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationHLA AntigensMethotrexateAdolescentAdultAgedFemaleHumansMaleMiddle AgedRegistriesRetrospective StudiesTransplantation, HomologousTreatment OutcomeYoung AdultHLA AntigensMethotrexateallo‐HSCTdosing regimensgraft‐versus‐host diseaseGVHD prophylaxismethotrexate

Identifiers

PMID41111282
PMCPMC12819093

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.